Unique Ingredient Identifier 3OWL53L36A is listed as a ingredient substance
| RN | 69-65-8 |
| EC | 200-711-8 |
| NCIT | C625 |
| RXCUI | 6628 |
| MF | C6H14O6 |
| INCHI KEY | FBPFZTCFMRRESA-KVTDHHQDSA-N |
| SMILES | OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO |
UNII 3OWL53L36A MANNITOL is commonly included in medications in the following forms.
| Route | Dosage Form | Potency |
|---|---|---|
| BUCCAL | GUM, CHEWING | 37.11 MG |
| BUCCAL | TABLET | 97.69 MG |
| BUCCAL/SUBLINGUAL | TABLET | 52.5 MG |
| IM - IV | INJECTION | 2.5 % |
| IM - IV | POWDER, FOR INJECTION SOLUTION | 30 % |
| IM - IV - SC | INJECTION | NA |
| IM - SC | INJECTION | NA |
| IM - SC | POWDER, FOR INJECTION SOLUTION | 2 % |
| INJECTION | INJECTABLE | 125 MG/VIAL |
| INTRAMUSCULAR | INJECTABLE | 42.5 mg |
| INTRAMUSCULAR | INJECTABLE | 5 % |
| INTRAMUSCULAR | INJECTION | 88.4 mg |
| INTRAMUSCULAR | INJECTION | 10.66 % |
| INTRAMUSCULAR | INJECTION, MICROSPHERES | 13.49 % |
| INTRAMUSCULAR | POWDER, FOR INJECTION SOLUTION | 11.93 % |
| INTRAMUSCULAR | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 8.5 % |
| INTRAMUSCULAR | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED, WITH | 3.6 % |
| INTRAMUSCULAR | POWDER, FOR INJECTION SUSPENSION | 4.5 %W/V |
| INTRAMUSCULAR | POWDER, FOR INJECTION SUSPENSION, LYOPHILIZED | 5.19 % |
| INTRAVENOUS | INFUSION | 17 % |
| INTRAVENOUS | INJECTABLE | 125 MG/1VIAL |
| INTRAVENOUS | INJECTABLE | 45 % |
| INTRAVENOUS | INJECTABLE | 41.5 MG/1ML |
| INTRAVENOUS | INJECTION | 4950 MG/100ML |
| INTRAVENOUS | INJECTION | 100 mg/1VIAL |
| INTRAVENOUS | INJECTION | 33.9 % |
| INTRAVENOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 100 MG/1VIAL |
| INTRAVENOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 4.8 % |
| INTRAVENOUS | INJECTION, SUSPENSION | 2.5 % |
| INTRAVENOUS | LIQUID | 4.1 % |
| INTRAVENOUS | LIQUID, CONCENTRATE, INJECTION | 6.13 % |
| INTRAVENOUS | POWDER | 45 % |
| INTRAVENOUS | POWDER FOR INJECTION DOSAGE FORM | 150 mg/1VIAL |
| INTRAVENOUS | POWDER, FOR INJECTION SOLUTION | 125 mg/1VIAL |
| INTRAVENOUS | POWDER, FOR INJECTION SOLUTION | 38 MG/1ML |
| INTRAVENOUS | POWDER, FOR INJECTION SOLUTION | 34 % |
| INTRAVENOUS | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 80 MG/1VIAL |
| INTRAVENOUS | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 36 mg/vial |
| INTRAVENOUS | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED, WITH | 3.94 % |
| INTRAVENOUS | SOLUTION | 4.15 % |
| INTRAVENOUS | SOLUTION, INJECTION | 6.25 % |
| INTRAVENOUS | SOLUTION, LIPOSOME, INJECTION | 10 % |
| INTRAVENOUS INFUSION | INJECTABLE | 125 MG/VIAL |
| INTRAVENOUS INFUSION | INJECTION | 51 mg/1mL |
| INTRAVENOUS INFUSION | INJECTION | 5.1 % |
| IV(INFUSION) | CONCENTRATE | 22 % |
| IV(INFUSION) | INFUSION | 3.85 % |
| IV(INFUSION) | INJECTABLE | 4.4 % |
| IV(INFUSION) | INJECTION | 4950 MG/100ML |
| IV(INFUSION) | INJECTION | 51 mg/1mL |
| IV(INFUSION) | INJECTION | 47 % |
| IV(INFUSION) | POWDER, FOR INJECTION SOLUTION | 75 % |
| IV(INFUSION) | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 42.5 MG/1VIAL |
| IV(INFUSION) | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 4 % |
| IV(INFUSION) | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED, WITH | 7.5 % |
| IV(INFUSION) | SOLUTION | 3.85 % |
| IV(INFUSION) | SOLUTION, CONCENTRATE | 4.4 % |
| IV(INFUSION) | SOLUTION, INJECTION | 20.67 % |
| NASAL | SOLUTION, SPRAY | 4.15 % |
| OPHTHALMIC | GEL | 5 % |
| OPHTHALMIC | POWDER, FOR SOLUTION | 5.6 % |
| OPHTHALMIC | SOLUTION | 47 MG/1ML |
| OPHTHALMIC | SOLUTION | 23 % |
| OPHTHALMIC | SOLUTION, DROPS | 16 mg/1mL |
| OPHTHALMIC | SOLUTION, DROPS | 4.6 % |
| OPHTHALMIC | SOLUTION, GEL FORMING, EXTENDED RELEASE | 4.35 % |
| OPHTHALMIC | SUSPENSION | 2.4 % |
| OPHTHALMIC | SUSPENSION, DROPS | 4 % |
| ORAL | CAPSULE | 297.2 MG |
| ORAL | CAPSULE (IMMED./COMP. RELEASE), HARD GELATIN | 264.8 MG |
| ORAL | CAPSULE, COATED PELLETS | 1.75 MG |
| ORAL | CAPSULE, DELAYED ACTION | 227 MG |
| ORAL | CAPSULE, DELAYED ACTION, ENTERIC COATED | NA |
| ORAL | CAPSULE, DELAYED RELEASE | 39.1 MG |
| ORAL | CAPSULE, ENTERIC COATED PELLETS | 236 MG |
| ORAL | CAPSULE, EXTENDED RELEASE | 6.42 MG |
| ORAL | CAPSULE, HARD GELATIN | 92 MG |
| ORAL | CAPSULE, SUSTAINED ACTION | 56.1 MG |
| ORAL | DISPERSIBLE TABLET | 58.3 MG |
| ORAL | GRANULE | 487.09 mg |
| ORAL | GRANULE, EFFERVESCENT | NA |
| ORAL | GRANULE, FOR ORAL SUSPENSION | 193.2 MG |
| ORAL | GRANULE, FOR SUSPENSION | 500 MG |
| ORAL | LOZENGE | 972 mg |
| ORAL | POWDER | 1100 MG/1PKT |
| ORAL | POWDER | 1100 MG/1SCP |
| ORAL | POWDER, FOR ORAL SOLUTION | 755 MG |
| ORAL | POWDER, FOR ORAL SUSPENSION | 1196.75 MG |
| ORAL | POWDER, FOR RECONSTITUTION | 293.62 MG/5ML |
| ORAL | POWDER, FOR SOLUTION | 45.86 MG/1ML |
| ORAL | POWDER, FOR SUSPENSION | 421.92 g |
| ORAL | POWDER, FOR SUSPENSION | 200 MG/5ML |
| ORAL | POWDER, FOR SUSPENSION | 0.339 g/236mL |
| ORAL | SOLUTION | 747 MG |
| ORAL | SOLUTION, INJECTION | 50 MG/1.7ML |
| ORAL | SUSPENSION | 500 MG/5ML |
| ORAL | SUSPENSION, SUSTAINED ACTION | 2464.6 MG/1PKT |
| ORAL | TABLET | 681.65 MG |
| ORAL | TABLET (IMMED./COMP. RELEASE), FILM COATED | 181.5 MG |
| ORAL | TABLET (IMMED./COMP. RELEASE), UNCOATED, CHEWABLE | 630 MG |
| ORAL | TABLET, CHEWABLE | 410.6 MG |
| ORAL | TABLET, COATED | 177.7 MG |
| ORAL | TABLET, CONTROLLED RELEASE | NA |
| ORAL | TABLET, DELAYED ACTION | 110.08 MG |
| ORAL | TABLET, DELAYED ACTION, ENTERIC COATED | 77.9 MG |
| ORAL | TABLET, DELAYED RELEASE | 213 MG |
| ORAL | TABLET, DISPERSIBLE | 104 MG |
| ORAL | TABLET, EXTENDED RELEASE | 384.75 MG |
| ORAL | TABLET, FILM COATED | 241.21 MG |
| ORAL | TABLET, FOR SUSPENSION | 270 MG |
| ORAL | TABLET, ORALLY DISINTEGRATING | 606.72 MG |
| ORAL | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE | 261.33 mg |
| ORAL | TABLET, SUSTAINED ACTION | 392.2 MG |
| ORAL | TABLET, SUSTAINED ACTION, FILM COATED | 274.97 MG |
| ORAL | TABLET, UNCOATED, LOZENGE | 187.6 MG |
| ORAL | TROCHE | 1035.18 MG |
| ORAL | WAFER | 500 MG |
| PARENTERAL | INJECTION | 4.4 % |
| PARENTERAL | POWDER, FOR INJECTION SOLUTION | 20 % |
| RESPIRATORY (INHALATION) | POWDER, FOR INHALATION | 0.051 % |
| SUBCUTANEOUS | INJECTABLE | 40 MG/1ML |
| SUBCUTANEOUS | INJECTABLE | 10 % |
| SUBCUTANEOUS | INJECTION | 100 mg/1VIAL |
| SUBCUTANEOUS | INJECTION | 40 MG/1ML |
| SUBCUTANEOUS | INJECTION | 10 % |
| SUBCUTANEOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 100 MG/1VIAL |
| SUBCUTANEOUS | POWDER, FOR INJECTION SOLUTION | 9 % |
| SUBCUTANEOUS | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 22.05 % |
| SUBCUTANEOUS | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED, WITH | 4 % |
| SUBCUTANEOUS | POWDER, FOR INJECTION SUSPENSION, LYOPHILIZED | 10 % |
| SUBCUTANEOUS | SOLUTION | 1.59 % |
| SUBCUTANEOUS | SOLUTION, INJECTION | 4.95 % |
| SUBCUTANEOUS | SUSPENSION, INJECTION | 1.21 % |
| SUBLINGUAL | TABLET | 204 MG |
| SUBLINGUAL | TABLET (IMMED./COMP. RELEASE), UNCOATED, BUCCAL | 157.48 MG |
| SUBLINGUAL | TABLET, ORALLY DISINTEGRATING | 10.25 mg |
| SUBMUCOSAL | SOLUTION, INJECTION | 2.94 % |
| TOPICAL | SOLUTION | 2.39 %W/V |
| TOPICAL | SOLUTION, DROPS | 1.6 %W/V |
| TOPICAL | SUSPENSION | 0.3 %W/W |
| TOPICAL | SUSPENSION, DROPS | 1.01 %W/W |
| TRANSDERMAL | PATCH, ELECTRICALLY CONTROLLED | 342.35 MG |
| TRANSMUCOSAL | TABLET | 180.19 MG |
| ORAL | CAPSULE | 336.6 mg |
| ORAL | CAPSULE | 266.7 mg |
| ORAL | CAPSULE | 258 mg |
| ORAL | TABLET | 97.93 mg |
| ORAL | TABLET | 35.45 mg |